INTRODUCTION
A three lipid-component parallel artificial membrane permeability assay (PAMPA) system was previously devised and evaluated (1) . Denoted A-PAMPA for anionic-PAMPA, A-PAMPA was designed to mimic the lipid composition of the enterocyte's plasma membrane and included 1,2-dioleoylsn-glycero-3-[phospho-L-serine] (PS18:1) as an anionic lipid component. A-PAMPA also consists of 1,2-dioleoyl-sn-glycero-3-phosphocholine (PC18:1) and cholesterol. Metoprolol flux across A-PAMPA was measured, as well as across three other PAMPA systems (1) . Results indicated that metoprolol transport across A-PAMPA was dominated by an ion-pair-mediated mechanism (i.e., metoprolol-PS18:1 complex).
The objective in the present study was to compare the performance of this three lipid-component PAMPA system to Caco-2 monolayers, in terms of screening for drug permeability values. Several development laboratories employ PAMPA membranes in candidate selection, in part because of other experimental approaches, such as Caco-2 and MDCK monolayers, are more labor-intensive and expensive (2) (3) (4) (5) (6) (7) (8) . However, A-PAMPA has not been previously evaluated to identify drugs that are likely to exhibit high permeability in Caco-2 BCS testing.
MATERIALS AND METHODS
Materials. PC18:1 and PS18:1 were purchased from Avanti Polar Lipids (Alabaster, AL). Hydrophobic microfilter plates (polyvinylidene fluoride, 0.45 μm) were purchased from Millipore Corporation (Bedford, MA). Caco-2 cells were obtained from ATCC (Rockville, MD). Drug compounds were either USP-or commercial-grade.
Permeability Measurements. A-PAMPA preparation and permeability methods follow previous descriptions (1, 5) . Hydrophobic filters were impregnated with 5 μL of membrane solution consisting of lipid in n-dodecane (5% w/v), where lipid consisted of PC18:1 (2.6%w/v), PS18:1 (0.9%w/v), and cholesterol (1.5%w/v). Permeability was calculated as described previously, using Eq. 3 in Palm et al. (7) . Mass balance ranged from 85-100%.
Caco-2 studies followed the cell culture and permeability methods previously described (9, 10) . Permeability was calculated as described previously (9, 10) . Mass balance ranged between 80-100%.
RESULTS AND DISCUSSION
Comparison of Drug Permeabilities. Permeability across A-PAMPA and Caco-2 are given at Table I. Figure 1 plots Caco-2 compound permeability versus A-PAMPA compound permeability. There was generally good agreement between permeability values from the two methods (linear r 2 =0.82, excluding coumarin and naproxen, which provided the highest permeabilities in both assays). Results here for A-PAMPA follow previous comparisons of PAMPA permeabilities to Caco-2 permeabilities (2,3,11-16). As suggestive of Fig. 1 and noted previously (8) , A-PAMPA permeability values were generally several-fold lower than Caco-2 permeability values.
Corti et al. (16) showed a good correlation of PAMPA and Caco-2 permeabilities (r 2 = 0.813), where PAMPA membrane employed Lipoid E80 (1.70%), n-octanol (96.2%), and cholesterol (2.10%). Lipoid E80 is fat-free egg lecithin and consists of largely (about 80%) phosphatidyl choline (17). A-PAMPA has some compositional similarity to the membranes in Corti et al. (16) . However, since oleic acid is a modest fatty acid component in Lipoid E80 (about 28% of all fatty acid), the phosphatidyl choline in Lipoid E80 is largely not PC18:1. Lipoid E80 also lacks PS18:1, which was included in the present three lipid-component PAMPA system as an anionic lipid component and an important contributor to ion-pair-mediated drug transport (1) .
Of the 21 compounds studied by Corti et al. and the 20 compounds studied here, there were 11 common compounds tested in both studies: acyclovir, atenolol, furosemide, hydrochlorotiazide, ketoprofen, metoprolol tartrate, naproxen, propranolol, ranitidine, theophylline, and verapamil. Among these drugs, naproxen showed the highest permeability here and in Corti et al. Likewise, acyclovir showed the lowest permeability. In general, permeability values from Corti et al. were several-fold larger than values from A-PAMPA here. Permeability values from A-PAMPA exhibited a wider range, which differed 500-fold between naproxen and acyclovir. Naproxen and acyclovir permeabilities in Corti et al. differed less than sixfold, although differences were easily detected.
PAMPA to Anticipate BCS Results. These results suggest that three lipid-component PAMPA system can be used to identify drugs that are likely to exhibit high permeability in Caco-2 BCS testing (18) . Prior to subjecting a compound to BCS-based permeability assessment, it is typically desirable to know whether the compound is likely to show high permeability. Because a BCS-regulatory submission requires a validated permeability method, a more facile method, such as A-PAMPA, has potential role in rapidly assessing whether a drug will likely show high permeability across Caco-2 monolayers.
In order to assess the utility of A-PAMPA to anticipate Caco-2 BCS classification results, each compound was classified as either high or low permeability. Table II shows the concordance between A-PAMPA classification results and Caco-2 classification results, employing metoprolol as the lower limit of high permeability (18) . Overall, six compounds exhibited lower permeability than metoprolol in A-PAMPA, with the remaining 14 (including metoprolol itself) showing high permeability. Of the 20 compounds, 15 were correctly predicted by A-PAMPA. Six compounds predicted by A- PAMPA to have low permeability showed low Caco-2 permeability. Nine compounds predicted by A-PAMPA to have high permeability (of 14 such compounds) showed high Caco-2 permeability. No compound was predicted by A-PAMPA to have low permeability but showed high Caco-2 permeability. However, five compounds predicted by A-PAMPA to have high permeability showed low Caco-2 permeability and were atenolol, chlorphineramine, disopyramide, indomethacin, and verapamil. As noted in Table I , the human percent dose absorbed of atenolol, chlorphineramine, disopyramide, indomethacin, and verapamil are 50%, 80%, 85.3%, 100%, and 98%, respectively. Hence, the disconcordance between A-PAMPA and Caco-2 classifications for indomethacin and verapamil were Caco-2 classification error. Meanwhile, the disconcordance for atenolol is A-PAMPA classification error. The absorption of atenolol is low and incomplete (19) . Likewise, but to a lesser extent given their fraction dose absorbed nears that of metoprolol, the disconcordance for chlorpheniramine and disopyramide was also A-PAMPA classification error.
From these five cases, A-PAMPA permeability "overestimated" BCS permeability classification based on Caco-2 permeability. These results support the use of A-PAMPA to screen compounds for subsequent BCS classification, with the expectation that only compounds that are likely to exhibit high permeability are subjected to BCS Caco-2 assay. One possible explanation for the mis-specification of atenolol, chlorphineramine, and disopyramide by A-PAMPA may be possible ion pairing between these weakly basic drug and PS18:1. Such ion pairing increases the permeability of metoprolol (1), but may perhaps have an even greater effect on atenolol, chlorphineramine, and disopyramide. Figure 2 plots human percent dose absorbed versus A-PAMPA permeability for the 20 compounds in Table I . Corresponding Caco-2 results are also plotted. The A-PAMPA profile is generally pushed towards the left, reflecting the lower A-PAMPA permeability of each compound, compared to Caco-2 permeability.
Based on human-fraction-dose absorbed data, A-PAMPA assay correctly classified all ten high permeability drugs as high permeability. Among the ten low-permeability drugs, four (atenolol, buproprion, chlorpheniramine, and disopyramide) was incorrectly classified as high permeability. The Caco-2 assay incorrectly classified three drugs: buproprion, indomethacin, and verapamil.
CONCLUSIONS
A three lipid-component PAMPA system was previously devised to mimic the lipid composition of the enterocyte's plasma membrane. The objective was to compare A-PAMPA system to Caco-2 monolayers, in terms of screening for drug permeability values. Results show good agreement for 20 drugs between PAMPA permeabilities and Caco-2 permeabilities, including concordance between PAMPA BCS classification and Caco-2 BCS classification. There was a modest tendency for the PAMPA system to "over-estimate" BCS permeability classification, such that the system appears to have utility to anticipate compounds that are likely to exhibit high permeability in a BCS Caco-2 assay. A-PAMPA Caco-2 Fig. 2 . Plots of human percent dose absorbed versus A-PAMPA permeability and Caco-2 permeability. For each of the 20 compounds, A-PAMPA permeability was generally less than corresponding Caco-2 permeability, typically by several-fold
